Figure 2
From: Resveratrol inhibits IL-33–mediated mast cell activation by targeting the MK2/3–PI3K/Akt axis
Effects of resveratrol on IL-33–mediated activation of NF-κB pathway in BMMCs. (A) Flow cytometry analysis of ST2 in BMMCs treated with or without resveratrol for 6 h (n = 3) (left), and representative histograms were shown (right). (B,C) Western blot analysis of phospho–TAK1 (B), phospho–IKKα/β, and phospho–p65 (C) in BMMCs stimulated with 1 ng/ml IL-33 for up to 10 min in the presence or absence of 25 μM resveratrol. (D) ChIP assay of p65 binding to the κB2 and κB3 regions of the TNF-α promoter in BMMCs treated with IL-33 or 1 μg/ml LPS in the presence or absence of resveratrol (n = 3). (E) Luciferase assay of NF-κB activity in BMMCs treated with IL-33 in the presence or absence of resveratrol (n = 3). *P < 0.05, **P < 0.01, ****P < 0.0001.
